2025-05-08T13:48:41-05:00 2024-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2024-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION ALZH 7812373800 34 WASHINGTON ST 230 WELLESLEY HILLS MA 02481 MARGARET E SMITH CEO 7812373800 2025-05-08 1 0 SANDY ROSS P01399337 4012742001 2025-05-05 2024 2025-03-06 01:10:19Z X CURE ALZHEIMER'S FUND MARGARET E SMITH 34 WASHINGTON ST 230 WELLESLEY HILLS MA 02481 37825374 0 X HTTP://CUREALZ.ORG/ X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. 9 8 33 85 0 0 36697205 30788755 0 0 1042285 964653 -14283 2269 37725207 31755677 26431117 28828950 0 0 4878104 5244116 0 0 2002303 3324327 2926002 34633548 36999068 3091659 -5243391 33488279 28586231 1727324 1722043 31760955 26864188 TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. ALL OVERHEAD EXPENSES ARE PAID BY THE BOARD OF DIRECTORS, TRUSTEES AND CORE GROUP OF SELECT DONORS, ALLOWING 100% OF GENERAL DONATIONS TO FUND OUR RESEARCH PROGRAMS. 0 0 30000392 28828950 IN 2024, CURE ALZHEIMER'S FUND SUPPORTED 120 RESEARCH PROJECTS AT 66 LEADING RESEARCH INSTITUTIONS, FOR RESEARCH OUTPUT OF $30 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF NEUROINFLAMMATION, THE GUT MICROBIOME, AND THE IMMUNE SYSTEM IN HEALTHY BRAIN FUNCTION. ADDITIONAL EXPENSES INCLUDE HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES. 3783862 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, WEBINARS, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 33784254 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 36 0 33 1 0 0 0 0 0 1 1 1 1 0 0 0 0 0 X 9 8 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X MARGARET E SMITH 7812373800 34 WASHINGTON STREET STE 230 WELLESLEY HILLS MA 02481 MARGARET E SMITH CEO 40.00 X X 426320 0 29113 HENRY MCCANCE CHAIR 5.00 X X 0 0 0 PHYLLIS RAPPAPORT TREASURER 5.00 X X 0 0 0 TIMOTHY ARMOUR DIRECTOR 3.00 X 0 0 0 RICHARD BIRNBAUM DIRECTOR 4.00 X 0 0 0 MARK FAGGIANO DIRECTOR (FROM 10/24) 3.00 X 0 0 0 MARY GREENHILL CAGLIERO DIRECTOR (FROM 10/24) 3.00 X 0 0 0 ROBERT GREENHILL DIRECTOR (TO 10/24) 3.00 X 0 0 0 KUMAR MAHADEVA DIRECTOR (FROM 12/24) 3.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 4.00 X 0 0 0 JOSEPHINE ANTONELLIS CFO 30.00 X 200226 0 7215 LAUREL LYLE SECRETARY & VP BOARD RELATIONS & DEV OPS 30.00 X 121094 0 4232 KATHARINE HERMAN EVP DEVELOPMENT 40.00 X 418581 0 30236 JULIE HARRIS EVP RESEARCH MGMT (TO 12/24) 40.00 X 296359 0 9851 BARBARA CHAMBERS EVP MARKETING & COMM. 40.00 X 267548 0 23094 LISA RAND VP MARKETING & COMM. 40.00 X 199320 0 18515 DANIEL HARPER VP DEVELOPMENT 40.00 X 195493 0 12700 JOHN SLATTERY SVP, PHILANTHROPIC PARTNERSHIPS 40.00 X 198792 0 6983 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 40.00 X 178255 0 25399 THIDAPHORN SENGSAVANH DIRECTOR OF DEVELOPMENT OPS 40.00 X 154055 0 24241 2656043 0 191579 16 0 1 0 PROPER VILLAINS LLC 855 BOYLSTON STREET 10TH FLOOR BOSTON MA 02116 CREATIVE AND PRODUCTION SERVICES 250941 1 236522 30552233 5918750 30788755 997714 997714 5684629 250276 5695860 272106 -11231 -21830 -33061 -33061 104000 236522 101731 2269 2269 31755677 0 0 966922 24417387 24417387 4411563 4411563 1833869 1068754 379849 385266 2771451 1588294 400877 782280 77621 44410 11100 22111 232224 131735 41248 59241 328951 195354 53661 79936 26187 8312 3225 14650 39123 39123 81000 81000 28594 28594 394657 189599 43291 161767 672478 672478 205044 66698 41069 97277 97396 11555 84399 1442 203490 116214 35011 52265 138200 51088 3723 83389 423373 338690 21790 62893 724 183 123 418 26363 4756 19517 2090 RESEARCH LAB EXPENSES 352275 352275 GIFT PROCESSING FEES 176286 176286 MISCELLANEOUS 60812 33909 5911 20992 36999068 33784254 1212511 2002303 1219384 2815537 3993426 322954 3783152 1707733 239429 246040 8688 724 0 7964 24112740 23255145 140148 230858 33488279 28586231 316299 167083 718427 600901 692598 954059 1727324 1722043 X 27791118 25165313 3969837 1698875 31760955 26864188 33488279 28586231 -5243391 346624 0 X 0 1 X 1 0 X 22874388 26547838 32354655 36697205 30788755 149262841 22874388 26547838 32354655 36697205 30788755 149262841 18414151 130848690 15472 4497 93408 992260 997714 2103351 151366192 317300 0.86450 0.87500 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 81000 0 0 81000 0 PART II-B, LINE 1(G) A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. 8688 724 7964 7964 ACCRUED PAYROLL AND RELATED 730551 LEASE PAYABLE 223508 954059 X 32073707 346624 346624 31727083 28594 28594 31755677 36970474 0 36970474 28594 28594 36999068 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 2618347 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 330913 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 918676 NORTH AMERICA 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 543627 0 0 0 0 0 0 4411563 0 4411563 BELGIUM IDENTIFYING MEDIATORS OF TAU MEDIATED NEURONAL NECROPTOSIS USING AN INNOVATIVE IN VIVO CRISPR SCREEN 230000 WIRE TRANSFER 0 BELGIUM PRECLINICAL ANALYSIS OF SYNAPTOGYRIN-3 OLIGONUCLEOTIDES TO TARGET TAUOPATHY 201250 WIRE TRANSFER 0 CANADA ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER 7763 WIRE TRANSFER 0 CANADA COMBINED HORMONE THERAPY AS A NOVEL TREATMENT FOR ALZHEIMER'S DISEASE IN THE FACE OF A METABOLIC CHALLENGE: INFLUENCE OF SEX AND GENOTYPE 201250 WIRE TRANSFER 0 CANADA ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER 47115 WIRE TRANSFER 0 CANADA APOE CONSORTIUM: EFFECT OF CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY ON AMYLOID AND CEREBROVASCULAR PATHOLOGIES IN ANIMAL MODELS OF ALZHEIMER'S DISEASE - YEAR 2/2 287500 WIRE TRANSFER 0 GERMANY SYSTEMATIC ASSESSMENT OF TANDEM REPEATS IN ALZHEIMER'S DISEASE (STAR-AD) 181500 WIRE TRANSFER 0 GERMANY SYSTEMATIC ASSESSMENT OF TANDEM REPEATS IN ALZHEIMER'S DISEASE (STAR-AD) - YEAR 1 OF 2 181500 WIRE TRANSFER 0 GERMANY STRUCTURAL MIMICRY IN MICROBIAL AND ANTIMICROBIAL AMYLOIDS CONNECTED TO NEURODEGENERATIVE DISEASES 200400 WIRE TRANSFER 0 HONG KONG APOE IN CHOROID PLEXUS FUNCTION AND RELATED ALZHEIMER'S DISEASE PATHOGENESIS 230000 WIRE TRANSFER 0 HONG KONG APOE CONSORTIUM: APOE GENOTYPE-SPECIFIC EFFECTS OF HUMAN YOUNG PLASMA ON CEREBROVASCULATURE AND AD PATHOLOGY 287500 WIRE TRANSFER 0 ISRAEL ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER 7763 WIRE TRANSFER 0 ISRAEL A PROPOSAL TO EVALUATE THE EFFECT OF BCG VACCINATION ON ALZHEIMER'S DISEASE DEVELOPMENT 121900 WIRE TRANSFER 0 ISRAEL DECODING MICROBIAL PRODUCTS MODULATING ALZHEIMER'S DISEASE TOWARDS PRECISION POSTBIOTICS TREATMENT 201250 WIRE TRANSFER 0 ITALY EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION 59950 WIRE TRANSFER 0 ITALY EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION 90045 WIRE TRANSFER 0 NEW ZEALAND CHARACTERIZATION AND VALIDATION OF TWO RECENTLY CREATED SHEEP MODELS OF ALZHEIMER'S DISEASE IN PREPARATION FOR USE AS A PRECLINICAL PHARMACEUTICAL TESTING MODELS 199926 WIRE TRANSFER 0 NORWAY TURNING UP MITOPHAGY TO BLUNT ALZHEIMER TAU PATHOLOGIES 200675 WIRE TRANSFER 0 NORWAY ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE 90000 WIRE TRANSFER 0 SINGAPORE MULTIDIMENSIONAL PROFILING OF TREM2-MUTATED OR APOE4-MUTATED MICROGLIA IN HUMAN BRAIN ORGANOIDS TO UNDERSTAND DYSREGULATED MICROGLIA NEURONAL CROSSTALK IN AD 201250 WIRE TRANSFER 0 SWEDEN ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE 108490 WIRE TRANSFER 0 SWEDEN ALZHEIMER'S DISEASE TAU CONSORTIUM: DEEP MASS SPECTROMETRY PROFILING OF TAU AGGREGATES IN ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES 287500 WIRE TRANSFER 0 UNITED KINGDOM ALZHEIMER'S DISEASE TAU CONSORTIUM: POST-TRANSLATIONAL MODIFICATIONS AND TAU ULTRASTRUCTURE; IMPACT OF ABETA ON TAU IN VIVO 198976 WIRE TRANSFER 0 UNITED KINGDOM CELLULAR VULNERABILITY TO PATHOLOGICAL TAU PROTEIN ACCUMULATION IN ALZHEIMER'S DISEASE 219880 WIRE TRANSFER 0 UNITED KINGDOM INVESTIGATING THE SERIAL PATHOLOGIES RELATED TO PLASMA BIOMARKERS IN NLFTAUM/H MICE; A NEW MOUSE MODEL FEATURING NEUROFIBRILLARY TANGLES AS A RESULT OF RISING AMYLOID WITHOUT MAPT MUTATIONS 200388 WIRE TRANSFER 0 UNITED KINGDOM ALZHEIMER'S DISEASE TAU CONSORTIUM: POST-TRANSLATIONAL MODIFICATIONS AND TAU ULTRASTRUCTURE; IMPACT OF ABETA ON TAU IN VIVO 167794 WIRE TRANSFER 0 26 0 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. FISHER ISLAND GOLF 340522 236522 104000 66019 7227 28485 340522 236522 104000 66019 7227 28485 101731 2269 1 BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON TX 77030 741613878 501 (C)(3) 138000 0 DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE BETH ISRAEL DEADONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 022155491 042103881 501 (C)(3) 201235 0 INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02215 042774441 501 (C)(3) 86250 0 BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE - SUPPLEMENT TO YR 1 (OF2) BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 575000 0 APOE: APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 275500 0 MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 201250 0 ROLE OF CHECKPOINT MOLECULES TIM-3 AND LAG-3 IN MICROGLIAL FUNCTION IN ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 228779 0 DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 195250 0 TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 201234 0 T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE BURKE NEUROLOGICAL INSTITUTE 785 MAMARONECK AVE WHITE PLAINS NY 106052523 133434924 501 (C)(3) 173007 0 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE CARNEGIE MELLON UNIVERSITY 5000 FORBES AVE PITTSBURGH PA 15213 250969449 501 (C)(3) 201250 0 INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501 (C)(3) 201279 0 NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 042263040 501 (C)(3) 201250 0 PRE-CLINICAL TESTING OF CDK4/6 INHIBITORS AS A THERAPEUTIC STRATEGY IN ALZHEIMER'S DISEASE USING AD TAUOPATHY MOUSE MODEL DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 562247203 501 (C)(3) 268750 0 PLASMA PROTEINS, SEX AND ALZHEIMER'S DIEASE: PROTEOMEWIDE ANALYSES OF THE UK BIOBANK AND FRAMINGHAM HEART STUDY DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 562247203 501 (C)(3) 192314 0 CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 562247203 501 (C)(3) 24957 0 UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501 (C)(3) 201250 0 UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 172500 0 VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 INVESTIGATING LYSOSOMAL MECHANISMS OF RISK AND RESILIENCE IN ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 150786 0 ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER INDIANA UNIVERSITY 1024 E 3RD STREET ROOM 132 BLOOMINGTON IN 47405 356001673 501 (C)(3) 200631 0 MODULATING THE LEVELS OF TAU-SEED INTERACTORS TO TREAT ALZHEIMER'S DISEASES INDIANA UNIVERSITY 1024 E 3RD STREET ROOM 132 BLOOMINGTON IN 47405 356001673 501 (C)(3) 180419 0 RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ROLE OF RIN3 AND BIN1 INTERACTION IN THE NEURONS FOR ALZHEIMER'S DISEASE DEVELOPMENT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 172500 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 VALIDATION AND CHARACTERIZATION OF COMPOUNDS MODULATING NEUROINFLAMMATION AND AMYLOID BETA UPTAKE IN MICROGLIAL CELLS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 1955000 0 THE CUREALZ ALZHEIMER'S GENOME PROJECT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 287500 0 MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE. MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 287500 0 BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 125000 0 THE IMPACT OF MUTATIONS IN THE LIGAND-BINDING DOMAIN OF CD33 ON ALZHEIMER'S DISEASE PATHOGENESIS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 CHARACTERIZING GUT BACTERIOME-MYCOBIOME SYNERGY IN CORRELATION TO AMYLIN-AB ANTIMICROBIAL SYNERGY IN ALZHEIMER'S DISEASE (AD) IN AD MOUSE MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 230000 0 ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 CHARACTERIZATION OF CNS-PENETRANT HDAC 11 SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 230000 0 SELECTIVE VULNERABILITY IN POSTERIOR CORTICAL ATROPHY MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 300000 0 UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 287500 0 ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 201227 0 CIRCUIT DYNAMICS IN APOE4 MICE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 201250 0 GROWTH, CHARACTERIZATION, AND DISTRIBUTION OF A NEURODEGENERATIVE DISEASE-FOCUSED FIBROBLAST/IPS CELL BANK TO SUPPORT MOLECULAR MODELS OF PATIENT-SPECIFIC VARIATION WITH VALIDATION IN MATCHED DONATED BRAIN TISSUES MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 172500 0 NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501 (C)(3) 300000 0 DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 201250 0 RESTORE MENINGEAL LYMPHATIC DRAINAGE TO ALLEVIATE WHITE MATTER DAMAGE AND CEREBRAL AMYLOID ANGIOPATHY IN A MODEL OF ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 201250 0 EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS MEDICAL COLLEGE OF WISCONSIN 8701 WATERTOWN PLANK ROAD MILWAUKEE WI 53226 390806261 501 (C)(3) 4721 0 RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501 (C)(3) 230000 0 THE ROLE OF IFITM3 AND -SECRETASE IN MICROGLIA NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE 900 ROCKVILLE PIKE BETHESDA MD 20892 520858115 501 (C)(3) 287500 0 BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 287500 0 NEUROIMMUNE CONSORTIUM: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO ALZHEIMER'S DISEASE NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 201250 0 MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE ONSET ALZHEIMER'S DISEASE IN WOMEN NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DR ABBOTT 1416 CHICAGO IL 60611 362167817 501 (C)(3) 286559 0 ALZHEIMER'S DISEASE TAU CONSORTIUM: THE ROLE OF AB - INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DR ABBOTT 1416 CHICAGO IL 60611 362167817 501 (C)(3) 345000 0 MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 201250 0 HARVARD MEDICAL SCHOOL-DEFINING A ROLE FOR THE MS4A GENES IN ALZHEIMER'S DISEASE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 201250 0 HARVARD MEDICAL SCHOOL-DISSECTING THE MODULATORY ROLES OF IL-17RD IN ALZHEIMER'S DISEASE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 201250 0 HARVARD MEDICAL SCHOOL-MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 230000 0 HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 187315 0 HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA ST JUDE CHILDREN'S RESEARCH HOSPITAL 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501 (C)(3) 92000 0 DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501 (C)(3) 201250 0 MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501 (C)(3) 230000 0 INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 201250 0 PROBING THE MOLECULAR UNDERPINNINGS OF G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATED PROTECTIVE MICROGLIAL RESPONSES TO ALZHEIMER'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 201250 0 ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 201250 0 THE ROLE OF ASTROCYTE-SECRETED LGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 201250 0 TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE CHICAGO IL 60637 362177139 501 (C)(3) 216287 0 IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUTMICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVE CHICAGO IL 60637 362177139 501 (C)(3) 250000 0 MICROBIOME CONSORTIUM: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO TX 78229 741586031 501 (C)(3) 201250 0 IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION UNIVERISTY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BOULEVARD SUITE 600 LOS ANGELES CA 90024 956006143 501 (C)(3) 201250 0 NOVEL AI DECODES AGING NEURONS UNIVERSITY OF CALIFORNIA DAVIS ONE SHIELDS AVENUE DAVIS CA 95616 943067788 501 (C)(3) 285851 0 NEUROIMMUNE CONSORTIUM: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 501 (C)(3) 201250 0 BIOINFORMATICS PLATFORM FOR MODELING ALZHEIMER'S PROGRESSION (MAP-AD PLATFORM) UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 501 (C)(3) 230000 0 ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 287500 0 BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 201250 0 DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA GA 30384 590624458 501 (C)(3) 24589 0 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 481091287 386006309 501 (C)(3) 148773 0 NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR FRANKLIN BLDG PHILADELPHIA PA 191046205 231352685 501 (C)(3) 285952 0 APOE: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY UNIVERSITY OF RHODE ISLAND 75 LOWER COLLEGE ROAD KINGSTON RI 02881 223011455 501 (C)(3) 201250 0 EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY - YEAR 2/2 UNIVERSITY OF ROCHESTER 910 GENESEE STREET SUITE 200 ROCHESTER NY 146113847 160743209 501 (C)(3) 287500 0 BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES CA 900898001 951642394 501 (C)(3) 227410 0 PROTECTION AGAINST ALZHEIMER'S WITH LONGEVITY-PROMOTING INTERVENTION 17A-ESTRADIOL UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501 (C)(3) 287276 0 ALZHEIMER'S DISEASE TAU CONSORTIUM: STRAIN REPLICATION IN MOUSE AND CELL MODELS UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 201250 0 IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 201250 0 ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE UNIVERSITY OF WASHINGTON 4300 ROOSEVELT WAY NE BOX 354965 SEATTLE WA 98105 916001537 501 (C)(3) 201250 0 ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDOLYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BOULEVARD WINSTONSALEM NC 27157 223849199 501 (C)(3) 201250 0 INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN LATE ONSET ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 219578 0 MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 200356 0 MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 ANTIVIRAL T CELL INFILTRATION TO THE MENINGES AND BRAIN INFLUENCES NEURODEGENERATION IN ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 APOE: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 287500 0 MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 2024 MORBY PRIZE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 123098 0 CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 52477 0 NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 258750 0 DISSECTING ALZHEIMER'S DISEASE PHENOTYPES IN DIRECTLY REPROGRAMMED PATIENT-DERIVED NEURONS WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 200532 0 HYPERTENSION, TAU AND NEURODEGENERATION WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 201250 0 TAU-INDUCED POSTSYNAPTIC DYSFUNCTION IN TAUOPATHY MODELS WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 402500 0 SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 201250 0 IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS YALE UNIVERSITY PO BOX 208239 NEW HAVEN CT 065208239 060646973 501 (C)(3) 199995 0 THE ROLE OF CALCIUM HOMEOSTASIS IN AXONAL SPHEROID FORMATION IN ALZHEIMER'S DISEASE 47 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X X X 0 0 0 0 0 0 0 0 0 MARGARET E SMITH CEO 407378 0 18942 0 0 0 10350 0 18763 0 455433 0 0 0 KATHARINE HERMAN EVP DEVELOPMENT 342381 0 76200 0 0 0 10350 0 19886 0 448817 0 0 0 JULIE HARRIS EVP RESEARCH MGMT (TO 12/24) 276634 0 19725 0 0 0 8891 0 960 0 306210 0 0 0 BARBARA CHAMBERS EVP MARKETING & COMM. 246348 0 21200 0 0 0 8403 0 14691 0 290642 0 0 0 LISA RAND VP MARKETING & COMM. 194120 0 5200 0 0 0 6268 0 12247 0 217835 0 0 0 DANIEL HARPER VP DEVELOPMENT 189293 0 6200 0 0 0 5959 0 6741 0 208193 0 0 0 JOSEPHINE ANTONELLIS CFO 190226 0 10000 0 0 0 6014 0 1201 0 207441 0 0 0 JOHN SLATTERY SVP, PHILANTHROPIC PARTNERSHIPS 189592 0 9200 0 0 0 6054 0 929 0 205775 0 0 0 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 172055 0 6200 0 0 0 5690 0 19709 0 203654 0 0 0 THIDAPHORN SENGSAVANH DIRECTOR OF DEVELOPMENT OPS 146855 0 7200 0 0 0 4883 0 19358 0 178296 0 0 0 PROPER VILLAINS LLC A PRINCIPAL OF THE INDEPENDENT CONTRACTOR IS THE SPOUSE OF A KEY EMPLOYEE 250941 CREATIVE AND PRODUCTION SERVICES 0 X 90 5629724 FMV X 1 250276 SALE PRICE X AUCTION ITEMS 8 38750 FMV 0 1 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH JP MORGAN AND BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION UPDATED ITS BYLAWS TO ESTABLISH THE POSITION OF DIRECTOR EMERITUS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE CEO AND ALL OTHER EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE.